Phathom Pharmaceuticals (PHAT) Common Equity (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Common Equity for 9 consecutive years, with -$344.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Common Equity rose 15.17% year-over-year to -$344.3 million; the TTM figure through Jun 2026 stood at -$344.3 million (up 15.17% YoY), while the FY2025 annual figure was -$438.2 million, down 72.79% from the prior year.
• Common Equity slipped to -$344.3 million in Q2 2026 per PHAT's latest filing, from -$337.0 million in the prior quarter.
• Across five years, Common Equity topped out at $38.0 million in Q1 2022 and bottomed at -$438.2 million in Q4 2025.
• Historically, Common Equity has averaged -$185.7 million across 5 years, with a median of -$167.8 million in 2024.
• Annual changes were most pronounced in 2023 — Common Equity jumped 351.43% — and 2024, when it plunged 1428.57%.
• Phathom Pharmaceuticals' Common Equity stood at -$74.8 million in 2022, then increased by 2.75% to -$72.8 million in 2023, then sank by 248.52% to -$253.6 million in 2024, then tumbled by 72.79% to -$438.2 million in 2025, then grew by 21.43% to -$344.3 million in 2026.
• Business Quant data shows PHAT's Common Equity at -$344.3 million in Q2 2026, -$337.0 million in Q1 2026, and -$438.2 million in Q4 2025.